Mehralivand S, Thomas C, Puhr M, Claessens F, van de Merbel AF, Dubrovska A et al. New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium. J Transl Med. 2024;22(1):71.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021.

Isaacs JT. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells? Am J Clin Experimental Urol. 2018;6(2):55–61.

Google Scholar 

Pisano C, Tucci M, Di Stefano RF, Turco F, Scagliotti GV, Di Maio M, et al. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: current and future clinical implications. Crit Rev Oncol Hematol. 2021;157:103185.

Article  PubMed  Google Scholar 

Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH. Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol. 2023;149(5):2259–70.

Article  CAS  PubMed  Google Scholar 

Uo T, Sprenger CC, Plymate SR. Androgen receptor signaling and metabolic and Cellular Plasticity during Progression to Castration resistant prostate Cancer. Front Oncol. 2020;10:580617.

Article  PubMed  PubMed Central  Google Scholar 

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocrine-related Cancer. 2012;19.

Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol. 2012;352(1–2):34–45.

Article  CAS  PubMed  Google Scholar 

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024.

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol. 2021;79(2):263–82.

Article  CAS  PubMed  Google Scholar 

Hodges C. Studies on prostatic cancer I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–7.

Google Scholar 

Santer FR, Erb HH, McNeill RV. Therapy escape mechanisms in the malignant prostate. Sem Cancer Biol. 2015;35:133–44.

Article  Google Scholar 

Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, et al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat Rev Urol. 2014;11(12):712–6.

Article  CAS  PubMed  Google Scholar 

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.

Article  CAS  PubMed  Google Scholar 

Thomas C, Baunacke M, Erb HHH, Füssel S, Erdmann K, Putz J et al. Systemic triple therapy in metastatic hormone-sensitive prostate Cancer (mHSPC): ready for Prime Time or still to be. Explored? Cancers. 2021;14(1).

Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of systemic treatments for metastatic castration-sensitive prostate Cancer: a systematic review and network Meta-analysis. JAMA Oncol. 2021;7(3):412–20.

Article  PubMed  PubMed Central  Google Scholar 

Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, et al. Triplet or Doublet Therapy in metastatic hormone-sensitive prostate Cancer patients: a systematic review and network Meta-analysis. Eur Urol Focus. 2023;9(1):96–105.

Article  PubMed  Google Scholar 

Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller C, et al. BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). J Clin Oncol. 2024;42:19.

Article  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [< sup > 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.

Article  CAS  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99–107.

Article  CAS  PubMed  Google Scholar 

Buteau J, Martin A, Emmett L, Iravani A, Sandhu S, Joshua A, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). J Clin Oncol. 2022;40:10.

Article  Google Scholar 

Chen Q-H, Munoz E, Ashong D. Insight into recent advances in degrading androgen receptor for castration-resistant prostate Cancer. Cancers [Internet]. 2024; 16(3).

Gao X, Iii H, Vuky J, Dreicer R, Sartor A, Sternberg C, et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:17.

Article  Google Scholar 

Petrylak D, Garmezy B, Shen J, Kalebasty A, Sartor O, Dreicer R, et al. 1803P phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations. Ann Oncol. 2023;34:S973–4.

Article  Google Scholar 

Petrylak D, Stewart T, Gao X, Berghorn E, Lu H, Chan E, et al. A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:TPS290–TPS.

Article  Google Scholar 

Bernard-Tessier A, Mulier G, Nay P, Baldini C, Albiges L, Colomba E, et al. Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): incidence and natural history. J Clin Oncol. 2023;41:221.

Article  Google Scholar 

Antonarakis E, Zhang N, Saha J, Nevalaita L, Shell S, Garratt C et al. REAL-WORLD ASSESSMENT OF AR-LBD MUTATIONS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER2023.

Crippa A, De Laere B, Discacciati A, Larsson B, Connor JT, Gabriel EE, et al. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 2020;21(1):579.

Article  PubMed  PubMed Central  Google Scholar 

Kreuz M, Otto DJ, Fuessel S, Blumert C, Bertram C, Bartsch S, et al. ProstaTrend-A Multivariable Prognostic RNA expression score for aggressive prostate Cancer. Eur Urol. 2020;78(3):452–9.

Article  CAS  PubMed  Google Scholar 

Ebersbach C, Beier A-MK, Hönscheid P, Sperling C, Jöhrens K, Baretton GB et al. Influence of systemic therapy on the expression and activity of selected STAT proteins in prostate Cancer tissue. Life. 2022;12(2).

Ebersbach C, Beier A-MK, Thomas C, Erb HHH. Impact of STAT proteins in Tumor Progress and Therapy Resistance in Advanced and metastasized prostate Cancer. Cancers. 2021;13(19):4854.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, et al. The glucocorticoid receptor is a key player for prostate Cancer cell survival and a target for Improved Antiandrogen Therapy. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(4):927–38.

Article  CAS  Google Scholar 

Erb HH, Bodenbender J, Handle F, Diehl T, Donix L, Tsaur I, et al. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE. 2020;15(8):e0237248.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desai K, Serritella AV, Stadler WM, O’Donnell PH, Sweis RF, Szmulewitz RZ. Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (rela) for patients with metastatic castration resistant prostate cancer. J Clin Oncol. 2023;41(16suppl):5062.

Article  Google Scholar 

Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, et al. Phase I/II trial of Enzalutamide and Mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2022;28(8):1549–59.

Article  CAS  Google Scholar